minimizes receptor desensitization Extended Regeneration Protocol Dose: 0.5 + 0.5 mg (variant 5 + 5 mg pen = 20 clicks / variant 5 + 10 mg pen = 13 clicks) Duration: 12 16 weeks Frequency: 1 daily Cycle Interval: 8-week rest Goal / Description: Long-term tissue recovery, collagen stimulation, and fat metabolism support Possible Side Effects CJC-1295 (No-DAC) and Ipamorelin are generally observed to be well-tolerated in research, particularly Ipamorelin due to its selectivity in not raising cortisol or prolactin levels
Conclusion Scientific exploration of the CJC-1295 and GHRP-2 peptide blend centers on receptor binding in the pituitary and hypothalamus, growth hormone and IGF-1 signaling pathways, possible synergistic interactions, and appetite regulation
Cellular uptake studies were performed in cellular environments with different oxygen concentrations in the cell lines 143B and K7M2
A 2024 paper in Physiology & Behavior characterised that ipamorelin and the related GHSR-1a agonist anamorelin inhibited cisplatin-induced weight loss in ferrets, framing one route by which the GHSR-1a agonist class engages cachexia research (PMID 39043357)
There's no single "best" optionit's about picking the right tool for the job
